Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBT: 2023-2025

Historic EBT for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$31.8 million.

  • Tonix Pharmaceuticals Holding's EBT fell 101.02% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.0 million, marking a year-over-year increase of 30.87%. This contributed to the annual value of -$136.7 million for FY2024, which is 39.20% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's EBT stood at -$31.8 million, which was down 15.06% from -$27.7 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's EBT peaked at -$15.8 million during Q3 2024, and registered a low of -$77.3 million during Q2 2024.
  • In the last 3 years, Tonix Pharmaceuticals Holding's EBT had a median value of -$27.3 million in 2023 and averaged -$29.8 million.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's EBT showed a top increase of 64.21% in 2025 and a maximum decrease of 101.02% in 2025.
  • Tonix Pharmaceuticals Holding's EBT (Quarterly) stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then slumped by 101.02% to -$31.8 million in 2025.
  • Its EBT stands at -$31.8 million for Q3 2025, versus -$27.7 million for Q2 2025 and -$16.1 million for Q1 2025.